A Study Of MCG In Cardiac Amyloidosis

NCT ID: NCT07218705

Last Updated: 2025-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-03

Study Completion Date

2027-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this observational study is to evaluate the utility of magnetocardiography (MCG) in diagnosing and monitoring disease progression in patients with amyloidosis, and to assess its effectiveness in comparison to other modalities, such as ECG.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amyloidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with amyloidosis

SandboxAQ CardiAQ Magnetocardiography

Intervention Type DEVICE

Magnetocardiography is a non-invasive, radiation-free imaging technique that detects the magnetic field generated by the electrical activity of the heart.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SandboxAQ CardiAQ Magnetocardiography

Magnetocardiography is a non-invasive, radiation-free imaging technique that detects the magnetic field generated by the electrical activity of the heart.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18 years on the date of consent
2. Ability for participant to comply with study requirements
3. Written informed consent

Exclusion Criteria

1. Pregnant or breastfeeding
2. Having an active atrial fibrillation episode as seen on most current 12-lead ECG
3. Active thoracic metal implants (including pacemaker, insertable cardiac monitor, or internal defibrillator).
4. External electrical pads or devices (e.g. Pacer pads, ECG electrodes, heart rate patch), that must remain on patient's chest during MCG scan
5. Inability to lie down in a supine/inclined position and stay still on the examination bed
6. Clinical conditions that in the opinion of the Investigator would compromise the safety of the patient or ability to complete the protocol
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mayo Clinic

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohamad Adnan Alkhouli

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mohamad Alkhouli, M.D., M.B.A.

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Andy Dang

Role: CONTACT

Phone: 507-255-7752

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Structural Heart Research Team

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

25-005053

Identifier Type: -

Identifier Source: org_study_id